Aug. 20 - Lilly’s neuro search, Rocket’s good news and MAHA takes aim at DTC drug ads

MAHA may take aim at pharma DTC ads; Rocket can resume gene therapy trial after FDA lifts hold; Omega’s Otello Stampacchia on the ‘reset’ changing biotech for the better

View online | Signup

Daily Dive

Aug. 20, 2025 | Today’s news and insights for biopharma leaders

BROUGHT TO YOU BY — Pfizer

Interactive: How Drugs Get Their Names

All potential drugs go through rigorous safety assessments during their development – and so do their names. Selecting a drug name can take years. See how in our interactive.

Lilly searching for new neuro chief as White set to retire

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly Neuroscience at the end of December.

MAHA may take aim at pharma DTC ads

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

Rocket can resume gene therapy trial after FDA lifts hold

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died earlier this year.

Navigating the oncology patent cliff: Strategic imperatives for big pharma

Key cancer drugs lose exclusivity soon—who’s ready to withstand the oncology patent cliff?

Q&A

Omega’s Otello Stampacchia on the ‘reset’ changing biotech for the better

Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the Omega Funds founder said.

Reduce Bioprocessing Costs for Biosimilars

Biosimilar manufacturers face pressure to control costs in a market projected to hit $73 billion by 2030. Learn scaling approaches for better ROI and balancing productivity with risk in this webinar.

Watch Now

From Our Library

Webinar - on demand